KIT exon 11
KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
Standard of care
GIST treatment depends on genotype, resectability, recurrence risk, and prior therapy. Complete resection remains central for localized disease. The usual advanced sequence is imatinib, then sunitinib, then regorafenib, then ripretinib, with molecular exceptions. Bezuclastinib plus sunitinib remains investigational as of November 7, 2026. Its target FDA action date is November 30, 2026. Pending review is not approval.
NOT INVESTMENT ADVICE. This is a general evidence review, not individualized medical advice. A line is shown only when the cited review or a trial record in this file states it.
No drugs selected. The grid shows every stated option.
How to read a tile
An empty cell reads “No standard.” The words on the tile carry the status. Border style repeats it.
| Subgroup | Localized, surgery | Neoadjuvant | Adjuvant | First line | Second line | Third line | Fourth line or later |
|---|---|---|---|---|---|---|---|
| KIT exon 11KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell. | |||||||
| KIT exon 9The review states KIT exon 9 often uses imatinib 400 mg twice daily. | |||||||
| PDGFRA D842VThe review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate. | No standard | No standard | No standard | No standard | No standard | ||
| Other PDGFRASensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18. | |||||||
| SDH-deficient or NF1The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1. | No standard | No standard | No standard | No standard | No standard | No standard | |
| Rare NTRK fusion or BRAF V600EThe review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence. | No standard | No standard | No standard | No standard | No standard | No standard |
KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.
The review states KIT exon 9 often uses imatinib 400 mg twice daily.
The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.
Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.
The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.
The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.
KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.
The review states KIT exon 9 often uses imatinib 400 mg twice daily.
The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.
No standard
Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.
The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.
No standard
The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.
No standard
KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.
The review states KIT exon 9 often uses imatinib 400 mg twice daily.
The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.
No standard
Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.
The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.
No standard
The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.
No standard
KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.
The review states KIT exon 9 often uses imatinib 400 mg twice daily.
The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.
Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.
The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.
No standard
The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.
No standard
KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.
The review states KIT exon 9 often uses imatinib 400 mg twice daily.
The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.
No standard
Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.
The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.
No standard
The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.
No standard
KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.
The review states KIT exon 9 often uses imatinib 400 mg twice daily.
The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.
No standard
Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.
The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.
No standard
The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.
No standard
KIT exon 11 is the sensitive KIT population named in INTRIGUE. The review states the usual sequence for sensitive KIT disease and does not give a separate label for every cell.
The review states KIT exon 9 often uses imatinib 400 mg twice daily.
The review states imatinib is ineffective for PDGFRA D842V, and that routine adjuvant imatinib is not appropriate.
No standard
Sensitive PDGFRA tumors that are not D842V follow the imatinib sequence in the review. Avapritinib is approved when the mutation is PDGFRA exon 18.
The review groups SDH deficient and NF1 associated disease for limited imatinib benefit. Olverembatinib is cited for SDH deficient disease, not for NF1.
No standard
The review names a rare NTRK fusion or BRAF V600E as a tissue agnostic match, not the usual KIT sequence.
No standard
The cited review names these options and does not assign them to a numbered line.